Ad-hoc

NEW YORK, NY, March 30, 2021 – The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc.

NEW YORK , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch , PhD will assume increased responsibilities with a new role of Chief Scientific Officer, which is in addition to his position as Co-Head of Research &

NEW YORK, NY – October 15, 2020 – Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1

NEW YORK , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering.

NEW YORK, NY – September 2, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion

NEW YORK, NY - August 25, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion aggregate

NEW YORK (NY) - August 19, 2020 – Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes”) in a private offering exempt from registration in accordance with Rule 144A and Regulation S under the

NEW YORK , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love , M.D. to the company's Board of Directors, effective immediately. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc., a leading global

NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S.

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc today announced the pricing of the initial public offering of 77,681,670 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to